MAP2K7 and thyroid gland carcinoma: These hybrid mutations occur in approximately 4% of anaplastic thyroid carcinomas (ATCs) and 9% of poorly differentiated thyroid cancers, resulting in sustained activation of the MAPK pathway through MEK signaling [17].